Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Third Harmonic Bio, Inc. (THRD)
P/B ratio as of 2023: 1.62
According to Third Harmonic Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.62. At the end of 2022 the company had a P/B ratio of 0.59.
P/B ratio history for Third Harmonic Bio, Inc. from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.62 |
| 2022 | 0.59 |
| 2021 | -14.08 |
| 2020 | -35.83 |